clinical trial · NCT07639021
A Research Study Comparing Different Ways of Increasing the Dose of NNC0662-0419 in Participants With Obesity
Novo Nordisk A/S·phase2·active not recruiting·n = 233
ObesityNNC0662-0419SemaglutideNNC0662-0419 PlaceboSemaglutide placebo
brief summary
The purpose of the study is to find out if NNC0662-0419 is safe and effective for treating participants living with obesity.
started
Jun 9, 2026
primary completion
Jun 14, 2027
completion
Jun 14, 2027
last updated
Sep 16, 2026
official title
Evaluation of Different Dose Escalation Regimens for NNC0662-0419 in Participants With Obesity
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol